Adar1 Capital Management, Llc Purchases 3,410 Shares of NextCure (NASDAQ:NXTC) Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc purchased 3,410 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were bought at an average cost of $5.00 per share, for a total transaction of $17,050.00. Following the completion of the acquisition, the insider directly owned 393,266 shares in the company, valued at $1,966,330. The trade was a 0.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, July 28th, Adar1 Capital Management, Llc acquired 6,400 shares of NextCure stock. The stock was bought at an average cost of $4.95 per share, with a total value of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc acquired 7,798 shares of NextCure stock. The stock was bought at an average cost of $5.00 per share, with a total value of $38,990.00.

NextCure Price Performance

Shares of NextCure stock opened at $5.03 on Friday. The company’s 50 day moving average price is $3.56 and its two-hundred day moving average price is $8.72. The firm has a market capitalization of $18.17 million, a P/E ratio of -0.29 and a beta of 1.42. NextCure, Inc. has a fifty-two week low of $1.55 and a fifty-two week high of $15.74.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.10) by $0.23. On average, analysts expect that NextCure, Inc. will post -7.89 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of NextCure in a report on Wednesday, July 15th. Wall Street Zen downgraded NextCure from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, NextCure has a consensus rating of “Hold” and an average target price of $19.00.

Institutional Investors Weigh In On NextCure

Institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new stake in shares of NextCure in the fourth quarter valued at about $160,000. Millennium Management LLC acquired a new position in shares of NextCure in the fourth quarter worth approximately $185,000. Geode Capital Management LLC boosted its holdings in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after acquiring an additional 3,636 shares during the last quarter. Cable Car Capital LP boosted its holdings in NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after purchasing an additional 5,300 shares during the period. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.